Comparative Pharmacology
Head-to-head clinical analysis: REGORAFENIB versus VITRAKVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REGORAFENIB versus VITRAKVI.
REGORAFENIB vs VITRAKVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Regorafenib is a multikinase inhibitor that targets various angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic kinases (KIT, RET, RAF). It inhibits tumor angiogenesis, growth, and metastasis.
Larotrectinib is a selective inhibitor of the tropomyosin receptor kinases (TRK) A, B, and C. It binds to the ATP-binding site of TRK kinases, preventing their activation and downstream signaling pathways, thereby inhibiting proliferation and inducing apoptosis in tumors with NTRK gene fusions.
160 mg orally once daily on days 1-21 of a 28-day cycle until disease progression or unacceptable toxicity.
100 mg orally twice daily
None Documented
None Documented
Clinical Note
moderateRegorafenib + Digoxin
"Regorafenib may increase the bradycardic activities of Digoxin."
Clinical Note
moderateRegorafenib + Digitoxin
"Regorafenib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateRegorafenib + Deslanoside
"Regorafenib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateRegorafenib + Acetyldigitoxin
"Regorafenib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life is 14–28 hours (mean approximately 20 hours), supporting twice-daily dosing with a 3-weeks-on/1-week-off schedule to allow washout and reduce toxicity accumulation.
Terminal elimination half-life is approximately 16.2 hours (range 12-20 h) in patients; supports twice-daily dosing.
Primarily fecal (approximately 71% of the radiolabeled dose) with renal excretion accounting for 19% (mostly as metabolites). Unchanged regorafenib is minimal in urine.
Primarily hepatic metabolism, with 39% recovered in feces (36% as unchanged drug) and 18% in urine (0.5% unchanged).
Category D/X
Category C
Kinase Inhibitor
Kinase Inhibitor